Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. (ACXP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
acxp · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Acurx Pharmaceuticals, Inc. (ACXP) measures how much investors pay for each dollar of the company's trailing earnings. ACXP's current PE ratio of N/A is calculated by dividing its stock price of $1.62 by its TTM earnings per share of -$5.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Acurx Pharmaceuticals, Inc.You ACXP | $3M | N/A | — | -$5.00 |
 Adial Pharmaceuticals, Inc. ADIL | $2M | N/A | — | -$11.93 |
 Aprea Therapeutics, Inc. APRE | $5M | N/A | — | -$1.93 |
 Aptevo Therapeutics Inc. APVO | $11M | N/A | — | -$8230.43 |
 BioCardia, Inc. BCDA | $5M | N/A | — | -$1.23 |
 Brainstorm Cell Therapeutics Inc. BCLI | $9M | N/A | — | -$1.11 |
 Creative Medical Technology Holdings, Inc. CELZ | $6M | N/A | — | -$2.52 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-5.31 | — | |
2024-12-31 FY2024 | — | $-16.56 | — | |
2023-12-31 FY2023 | — | $-23.01 | — | |
2022-12-31 FY2022 | — | $-22.36 | — | |
2021-12-31 FY2021 | — | $-24.96 | — | |
2020-12-31 FY2020 | — | $-9.28 | — | |
2019-12-31 FY2019 | — | $-15.81 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Acurx Pharmaceuticals, Inc. (ACXP) measures how much investors pay for each dollar of the company's trailing earnings. ACXP's current PE ratio of N/A is calculated by dividing its stock price of $1.62 by its TTM earnings per share of -$5.00.
Frequently asked questions
ACXP pe ratio · 6 questionsACXP's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.62 and TTM EPS of -$5.00. Data sourced from Financial Modeling Prep via ACXP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Acurx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08